ArticleJournal of the National Cancer Institute2026
Lymphocyte count and risk of chronic lymphocytic leukemia.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundElevated absolute lymphocyte count is often used as a first indication for diagnostic investigation of chronic lymphocytic leukemia (CLL). The absolute risk of CLL as a function of age, sex, and absolute lymphocyte count has not been described.
methodsWe used information about prediagnostic absolute lymphocyte cell count on 475 399 longitudinally followed research participants from UK Biobank, with a median follow-up of 11.6 years, during which 854 participants were diagnosed with CLL. A CLL risk model was developed based on sex, age at recruitment, and prediagnostic absolute lymphocyte count using flexible parametric survival modelling.
resultsCompared with research participants who had absolute lymphocyte counts below 2 × 109/L, the risk of CLL was almost 8 times higher for individuals with absolute lymphocyte counts of 3 to 4 × 109/L (hazard ratio = 7.76, 95% CI = 6.24 to 9.65). The absolute risk of CLL was 2-fold higher in male than in female individuals. For 60-year-old persons with absolute lymphocyte counts of 5 ×109/L, 10-year CLL risk was estimated at 6.5% (95% CI = 5.6% to 7.5%) for men and 3.5% (95% CI = 3.0% to 4.1%) for women. The 10-year risk of CLL for participants with absolute lymphocyte counts of 5 ×109/L varied between 0.91% (95% CI = 0.68% to 1.2%) for a 40-year-old woman and 12% (95% CI = 11% to 15%) for a 70-year-old man.
conclusionThe absolute risk of CLL is strongly influenced by age, sex, and absolute lymphocyte count. A crude absolute lymphocyte count cutoff to indicate further investigation for CLL without taking age and sex into consideration will identify some individuals who are at low risk. These results may be considered when establishing guidelines for clinical management in patients with elevated absolute lymphocyte counts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.